<SEC-DOCUMENT>0001104659-12-020243.txt : 20120322
<SEC-HEADER>0001104659-12-020243.hdr.sgml : 20120322
<ACCEPTANCE-DATETIME>20120322171338
ACCESSION NUMBER:		0001104659-12-020243
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20120322
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120322
DATE AS OF CHANGE:		20120322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		12709888

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a12-7828_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT<br> Pursuant to Section&nbsp;13 or 15(d)<br> of the Securities Exchange Act of 1934</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported):<b>&#160; March&nbsp;22, 2012</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-50626</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">91-1707622</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other jurisdiction</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">200 Connell Drive, Suite&nbsp;1500<br> Berkeley Heights, NJ 07922</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">  <br>  </font></b><font size="2" style="font-size:10.0pt;">(Address of principal executive offices and zip code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code:<b> (908) 517-7330</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former Name or Former Address, if Changed Since Last Report)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction A.2. below):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b)) </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)) </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\106728\12-7828-1\task5206793\7828-1-ba.htm',USER='106728',CD='Mar 23 01:47 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;1.01&#160;&#160; Entry into Material Definitive Agreement.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On March&nbsp;22, 2012, Cyclacel Pharmaceuticals,&nbsp;Inc. (the &#147;<b>Company</b>&#148;) entered into a purchase agreement (the &#147;<b>Agreement</b>&#148;) with certain existing institutional stockholders (the &#147;<b>Investors</b>&#148;) and raised gross proceeds of $3,036,000 to fund certain litigation-related expenses on certain intellectual property (the &#147;<b>Litigation</b>&#148;) and otherwise for general corporate purposes.&#160; Under the terms of the Agreement, the Investors purchased 4,688,079 shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;<b>Common Shares</b>&#148;) at a per share purchase price of $0.6476, which is equal to the 10-day average closing price of the Company&#146;s common stock for the period ending on Wednesday, March&nbsp;21, 2012, and obtained certain contractual economic rights, generally related to the Litigation (the &#147;<b>Economic Rights</b>&#148;), including rights to receive additional shares (&#147;<b>Additional Shares</b>&#148;) or warrants (&#147;<b>Warrants</b>&#148;) to purchase shares of common stock (&#147;<b>Warrant Shares</b>&#148;) in certain circumstances.&#160; The Common Shares are subject to a lock-up for a period of one year from the date of issuance.&#160; The Economic Rights are transferable at any time to an affiliate of each respective Investor, and are subject to a right of first refusal in favor of the Company with respect to each proposed sale, transfer or other disposition.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Common Shares described above were offered and sold, and the Additional Shares and Warrants, if and when issued, will be sold, pursuant to&nbsp;an exemption from the registration requirements of the Securities Act of 1933, as amended (the &#147;<b>Securities Act</b>&#148;), pursuant to Section&nbsp;4(2)&nbsp;of the Securities Act and/or Regulation&nbsp;D promulgated thereunder on the basis that, among other things, the transaction did not involve a public offering, the Investors are accredited investors, the Investors took the securities for investment and not resale and the Company took appropriate measures to restrict the transfer of the securities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Agreement also provides for certain registration rights with respect to the Common Shares, and if issued, the Additional Shares.&#160; The Company is required, upon demand of a majority-in-interest of the Investors, to use its commercially reasonable efforts to file a registration statement for the resale of such securities, and to cause such registration statement to be declared effective no later than 90 days following the date of such Investors&#146; demand (or 180 days following such date, if the Securities and Exchange Commission determines to review the registration statement at issue). The Investors are also entitled to piggyback registration rights, subject to cut-backs, as more fully set forth in the Agreement. The Company also agreed to other customary obligations regarding registration, including indemnification and maintenance of the effectiveness of the registration statements.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company intends to file the Agreement as an exhibit to its next periodic report and plans to seek confidential treatment of certain terms in the Agreement at such time.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;3.02 Unregistered Sales of Equity Securities.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The response to this item is included in Item&nbsp;1.01, Entry into a Material Definitive Agreement, and is incorporated herein by this reference in its entirety.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;8.01 Other Events.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On March&nbsp;22, 2012, the Company issued a press release announcing the offering described in Item 1.01 above.&#160; A copy of the press release is attached as Exhibit&nbsp;99.1 to this Current Report on Form&nbsp;8-K, and the information contained therein is incorporated herein by reference.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_012628_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\106728\12-7828-1\task5206793\7828-1-ba.htm',USER='106728',CD='Mar 23 01:47 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Neither the filing of the press release as an exhibit to this Report nor the inclusion in the press release of a reference to our internet address shall, under any circumstances, be deemed to incorporate the information available at our internet address into this Report. The information available at our internet address is not part of this Report or any other report filed by us with the Securities and Exchange Commission.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;9.01 Financial Statements and Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp;Exhibits</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="11%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit<br>   Number</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="86%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:86.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="86%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:86.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="86%" valign="top" style="padding:0in 0in 0in 0in;width:86.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press   release, dated March&nbsp;22, 2012</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_012757_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\106728\12-7828-1\task5206793\7828-1-ba.htm',USER='106728',CD='Mar 23 01:47 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt .3in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Paul McBarron</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul   McBarron</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Executive   Vice President&#151;Finance,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer and<br>   Chief Operating Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   March&nbsp;22, 2012</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_012911_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\106728\12-7828-1\task5206793\7828-1-ba.htm',USER='106728',CD='Mar 23 01:47 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a12-7828_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="174" height="65" src="g78281mmi001.jpg"></font></p>    </td>
<td width="50%" style="padding:0in 0in 0in 0in;width:50.0%;">
<p align="right" style="margin:0in .25in .0001pt 0in;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cyclacel Pharmaceuticals,&nbsp;Inc.</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="571" height="26" src="g78281mmi002.jpg"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL ANNOUNCES $3.0 MILLION FINANCING TO FUND ONGOING LITIGATION EXPENSES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ON CERTAIN INTELLECTUAL PROPERTY</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Berkeley Heights, NJ, March&nbsp;22, 2012 </font></b><font size="2" style="font-size:10.0pt;">&#150; Cyclacel Pharmaceuticals,&nbsp;Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &#147;Cyclacel&#148; or the &#147;Company&#148;), today announced that the Company entered into a purchase agreement with certain existing institutional stockholders raising $3,036,000 in gross proceeds.&#160;&#160; The proceeds from the financing will be used to fund ongoing litigation-related expenses on certain intellectual property and otherwise for general corporate purposes.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the terms of the purchase agreement, the investors purchased 4,688,079 shares of the Company&#146;s common stock at a price of $0.6476, which is equal to the 10-day average closing price of the Company&#146;s common stock for the period ending on Wednesday, March&nbsp;21, 2012.&#160; In addition to the common stock, investors received contractual rights to receive in cash 10% of any future litigation settlement on certain intellectual property, subject to a cap, or alternatively, in lieu of a cash payment, either warrants to purchase common stock in certain situations or additional shares as part of any settlement in a possible related, alternative transaction.&#160;&#160; The shares issued at closing are subject to a lock-up period of one year from the date of issuance.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The shares of common stock described above were offered and sold, and the additional shares and warrants, if and when issued, will be sold, pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), pursuant to Section&nbsp;4(2)&nbsp;of the Securities Act and/or Regulation D promulgated thereunder on the basis that, among other things, the transaction did not involve a public offering, the Investors are accredited investors, the Investors took the securities for investment and not resale and the Company took appropriate measures to restrict the transfer of the securities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Cyclacel Pharmaceuticals,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.&#160; Sapacitabine (CYC682), an orally-available, cell cycle modulating, nucleoside analogue, is in a Phase 3 trial being conducted under a SPA with the U.S. FDA for the front-line treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes, lung cancer and chronic lymphocytic leukemia.&#160; Seliciclib (CYC202 or R-roscovitine), an orally-available, CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine.&#160; Cyclacel&#146;s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair&#174; Cream for radiation dermatitis, Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges for xerostomia.&#160; Cyclacel&#146;s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.&#160; Please visit www.cyclacel.com for additional information.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">200 Connell Drive, Suite&nbsp;1500, Berkeley Heights, NJ&nbsp; 07922 USA&#160; T: +1 (908) 517 7330 F: +1 (866) 271 3466</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Dundee Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">www.cyclacel.com&#160; &#150;&#160; info@cyclacel.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105621\12-7828-1\task5206750\7828-1-mm.htm',USER='105621',CD='Mar 23 01:27 2012' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel&#146;s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;intends,&#148; &#147;continues,&#148; &#147;forecast,&#148; &#147;designed,&#148; &#147;goal,&#148; or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form&nbsp;10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov.&#160; Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contact for Cyclacel Pharmaceuticals,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investors/Media: Corey Sohmer, (908) 517-7330, csohmer@cyclacel.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#169; Copyright 2012 Cyclacel Pharmaceuticals,&nbsp;Inc.&#160; All Rights Reserved.&#160; The Cyclacel logo and Cyclacel&#174; are trademarks of Cyclacel Pharmaceuticals,&nbsp;Inc.&#160; Numoisyn&#174; and Xclair&#174; are trademarks of Sinclair Pharma plc.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONFIDENTIAL DRAFT * * * NOT FOR DISTRIBUTION</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_012653_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105621\12-7828-1\task5206750\7828-1-mm.htm',USER='105621',CD='Mar 23 01:27 2012' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g78281mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g78281mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!!`*X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^LG7?$6G
M^'[827<A,C#]W"G+O_@/>CQ%KL/A_29+R4!I#\L4>?ON>@^G<UYYI^C'54F\
M3^*;EDLC\P4\-+Z`>B]@!UKLP^'4U[2I\/XM]D<&+Q<H/V5+66_DEW87'B_Q
M/XCG:'28)88\_=MERP_WG[?I56?PCXCGP^HW$49/(^UW@S_,UIKJ6N:_`T.@
MP1Z1HL7!ER(P!ZEOZ#\36'/IOAZ)C]L\1RW,_P#$;>W+C_OICS7JT_<]V"4?
M))R?SL>%57/[TVY>;:BODGN2)X7\268,M@WF!>2;*Z!/Y`@U9T_QUK^C7'V>
M_#7*J?FBN5*R#_@77\\U0BTO2)G4Z7XB$4_\*W430\_[XR!5RYU*^LV33O%=
MFUY;,,QS$@RJ/[T<@^\/8U<DJFDTI?*S^5]_P(@W2]ZG)Q\[J4?G;;\3TS0O
M$>G^(+<R6DF)%'[R%^'3\.X]ZUJ\GFM;;X=6,OC*>[>\T^.,?9X8DVR2^9@*
M&SP!SG\*Z_P#XXM/'WA]M4M;:6V:.8P2PR'=M<`'@]QAASQ7A8F%.-2U)W1]
M-A)UITKUE9_GYG4T445@=(4444`%%%%`!1110`4444`%%%%`!1110!YYJ<)\
M7?$!=.8DZ?IJYE`Z$\9'XG`^@-)J/E^*-?N%N)/*\/:,/WFTX#L!R!CZ8^@]
MZF\(3"'P_KVOL?WDTLLFX\D!02/U)J*UTTGPOH&C<@ZK/]HNCW9`-[?IM%>O
M?DERK3ET7EI>3]3P;<\>9Z\_O/SUM%>A4NMNK6D6HZN9+31`=FGZ9;##S^G`
M]?\`..\C"ZLHU\NQ\/:%$>46^8/,1[]36JR2WFIR7<`5;B29K#3B5RMM&F?,
ME`Z9X./P%=!8^'=,L5)%JDTS<R3SCS)'/<EC43KQ@DG]W]?BW>[-*>%E4DVG
M\_Z_!*R2MN<!=Q&2U,^IZ-IM_9#[][H[!7C]R!_44]9M)\(:`^IZ]?I>^&)V
M06D;P%W$C$D?+CY>`<XX-==?Z3I-AJ=I=6T)MM0E9EACM\HEPP0ML?`(`P#R
M:6Q\/&[FGOM9#R_;88?,TF=UGM;5T'/E@KCKWK*KC+PY8?U_7=6]#>A@.6IS
MU/Z]=KKR=_4Y?1O#_B?5_%.LGQ#=6FH>"[Z+-G:$`J4)!CPN`5*KU/K^8[K1
MM#TSP]IR:?I-E%:6JDD1QCN>I)ZD^YK0````&`.@K+\0^(-.\+Z)<:MJDQCM
M80,[1EF)X"J.Y)K@/3-2BN`MO$WC[58%OK#P=9V]FXWQQ7]_LGD7M\H4A#[&
MKDGC.^TSQCI&CZWID=G:ZM;@V]PLN_9<@#="QQC/8$=<C\`#LZ*Y7Q1XLGTG
M6='T+2K1+W5M2E.(W8JL,*_?E8CL.WKS5/5_'ES_`,)#-X=\,:,^LZK;J&NF
M,PAM[;/0.YSEO8?XT`=M17+Z1JGBT/=#7]$L+>&.!I8[BTO#(&8?P%2H(XSS
MTXJ7P)XEE\7^#;#79K9+:2YWYB1BP7:[+U/^[F@#HZ*HZSJEOHFBWNJ71Q!:
M0M,_N%&<?4]*Y7X>^/+GQ?\`;[;4],&F:C:B*7R-Y;=#*@9&Y`_SB@#N**YC
MQ9XTM_#,EI8PV<^I:S?$BTT^W(#R8ZLQ/"J/4_T.*ECJWCYKZV.H>&-,CLI9
M5640ZCNE@0GECE<-@<X'I0!V5%><MXW\5ZCXOUW1-!T#3KE-)DC1Y;B\,9;>
MN1Q@^AJWXD\9Z]X3^'\NO:KI%FNH1SK']EBN"T>UF`!W8Z_A0!W=4#K>FK(R
M->1*5)4Y.!D=?YU<AD\V".0C!=0V/J*PY/!^E2SRR21L?,(+#/)QP,GV&0/K
MWH`QO#=FTG@#5-/&3(KW,)QU)Y%7+,H\?A"]!_=B$P\=`S1<#\UQ5C2Q_9?B
MS4]/?B*^Q>P'L6Z2#ZYP:CMK(1K>>'G?RGC?[5I\GHN[<,?[C<$>A'K7H3G>
M4GWU^35G]QY<*?+&*[:?.+NOOM^1-ID8@FM-_!AGN8&]`SOO7\P!^==%6#&S
M7)EF$'^D85+ZS!P0PZ.A]?0]QCN*O6UXS#8DT4V/[Y\N0?[RXZ_E7-53D[G7
M1DHJW]=BXEO%'-+,D8627'F,.K8&!G\*DK.>_*2@/)'N'2"#]X['^@_SFKZM
MN49&UL`E<]*R<6MS>,U+8=7F7QC:.)/"4UZ&_LR/7(6NC_"!S@M[=:]-JAK6
MC:?X@TFXTO4[=;BTG7:Z-^A![$'D&I*+X((R.17-^.O#<'BCPI=V4C^5/$/M
M%K<#[T,R<JP_D?8FL*#X>^(--B2STCX@:I;:<@VI!/;13NB]@KMR`.G2NVCL
MW724LI;F29Q`(FGD`W.=N"QQQD]:`//OA#%/KVG3^.=7E2XU?5/W`95PL,,9
MVA%';+*6/KQ3?@Z\8_X2Z"?(U1=<G:Z#GYR#]TGVX;]:ZWP3X67P9X4M=#6[
M-V+<N?.,>S=N8MTR?7UK.UWX>VVI:Z=?TG5+S0]99-DMS9D%9@.GF(>&[?D*
M`.IU'_D&7?\`UQ?_`-!-<3\%/^22:)_VV_\`1SUJZ)X9UVRDN7UCQ;=:N)H&
MA6-K6.%$SCYL+U/'KW-<UH_PS\5:!I4.F:7\1+BWLH,^7$-+B;;DECR6)ZDF
M@"/XR:[9QQZ+X9NII([;4;I9;\Q1M(PMHV!(VJ"?F;`_`UBWWCGP]%\5/#VN
MZ//.(;J,Z7J"R6DL*A"1Y3990.&_05Z1I_A/[+XUO?$]U?M=W,]I':0(8@H@
MC7EL')SN;YNV*L>,?#%OXP\,7>BW$IA$VTI,J[C$ZD$,!D>GKWH`XZ)EB_:-
MG%\5!ET,"PW#KAP6"^_#_A7IU<IKG@2S\2:5IL6I7=P-4T]%\C5+4^5,C@`%
MAUZD9(YJMI_A'Q/;:A;RWGCZ_N[.&17-O]CB0R`$':SCD@XP>E`'$Z1:>*+K
MXJ^._P#A&]5L;';/;^=]JMS+O^0XQCICG\ZO_%N'5;?X+SQZW=P7=^+F+S)K
M>/RT8>9QA?IBM>Z^'.MQ^*=7UO1/&<VE'5'1YH5L$E'RC`Y9OKV'6K>L^`M1
M\1>`YO#FL>)9+NYDG67[>;15(`((78I`[=<]Z`.SL_\`CR@_ZYK_`"J:N(TG
MPEXNL-1M9KOQ_/>VD+@R6K:;$@D4?P[@<CZUV]`&5KNER:A;Q36CK'J%H_FV
MTAZ;NZG_`&6'!JO%)!XDL%=2]GJ-J_3_`):6TO<$=P?R85NUE:CHPNKE;ZSG
M-GJ*+M$RC(<?W77^(?J.U;0GHHMVML_ZZ'/4IN[E%7ONN_FO,IR7$;31IJZG
M3[]/ECNXVQ')_NL>,'^ZWZ]:O-!?.H#K8WBXX:12A(_)A55M8EMD,.NZ>T2D
M8,\*&:!Q[X&5^C#\:;!'X<F&^SNX(PW:WNS'^BL,5HT[:K]49)INR>OGH_FN
MOK8MB#4%C(\RSL8P,L84W$?B<`?B#5:VO($D:#1XVOIG8>?=.Y*#']Y^Y]%7
M]*CN(_#-OB2\NK>0CI]IN3+^C$Y_*GKK<MV@AT/3I)5'`GF0PP*/;(RWT`_&
MCE;6B_1?\'[PYDG9O7RU?R73[C>HK/TW3YK0R3W=Y)=74V-['Y44#HJ+T`Y^
MI[FM"N:22=D[G7%MJ[5@HHHI%!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`5YIXU_P"/F3_?HHKMP'\4\W-/X`WP1_Q]+_UT_I7IM%%/'_Q0RO\`@!11
B17">D%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g78281mmi002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g78281mmi002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MP``+"``:`CL!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/?Z****************R-7O;B"^L;:"9(5G+!I&4'&!
M[U+HE_+?V;O-M+1RM'O08#@=Q6E67KM[/8V<36[*KR3+&689P#2:7>W$UY>6
ML[K,+<@+,BX#9'0^XK5JGJUS)::5<W$)`DC3*Y&>:@T6YEN[7S9;R*X8A21&
MH'EG'(-:=9^M7LNGZ7)<0J&<$#)&0N3U-2:9*\UH)'NX[H,<B2-=HQZ8JY6;
MKE]-IVFF>$#=O"EB,A`>Y%6-.D>6T5WNH[G<<B2-=H(^E6J***P+_4;Q=3O(
M(KF*&.WMQ*-R`[CZ$UK:?</=Z?!<2)L>1`Q7TJS6)K6HW%I?V<$5S%;QRAM\
MDB@@8K7@)-O&6D$A*C+J,!O>I*RYKZ=/$5M9*5\F2%G88YR,]ZU**P+G4KD>
M('LA>PVT2JK+O0$L3C@<UOT5A:GK$]IJT44>W[-'L^T$C)&XX%;M%8FJZE/!
MJD%FEQ':QR(6\Z1-P8_W:VESL&2"<<D=Z6L'5M2N+?6(;1+N&UA>(N9)$!&<
MFMU,[%R=QQR1WI:*********************************R]2TQK_4+&4K
M&T,);S%?N"/2M*.-(D"1HJ(.BJ,`4ZLW6M/DU&VABCV?+,KMO/!`SFDTFPGT
MTW%N2C6I<O#@_,H/4&M.JFJ6KWNF7%M$5#R)@%NE1Z3;W-M:B&XBMTV*JJ82
M3NP.IXZU?J"\%P;9A;)$\A_AESM([]*I:)IDNG0S^<R;YI"Y2/[J>PK4JM?"
MY:V(M8X9')Y6;.TCOTJKH>FR:99O'*R%Y)#(53[JY["M.BBBN?U'0);[4+JX
MW(NZ)1"V>5=?7VK;MO.^S1_:`OG!1OV'C/M4M8^K:==76H6EU;K`X@#928D`
MY_"M6'>(4\Q55]HW!.@/M3ZQ[^QO6UF"_M!`WEQ%"LK$=<^@K7&=HSC..<4M
M8DVG7JZ])?0QVTD;HJ8E)R,8Y'%;=%<]/X?GNX]0>6X99KARR*C?)@?=W<5M
MVBRI:0I.5,JH`Y4Y!-35D:W8WNHQ?9H4M3"X&7DSN0YZBM*WA^SVT4.XMY:!
M<GO@5+6+J.G7<NL0WMNEO(L<10I,2`3D^U;*YV#<`&QR!TI:************
M****@N+RWM-OGRJF[IGO4']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQ
MI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L
M:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;
M&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&
MG_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQ
MI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L
M:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;
M&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&
MG_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQ
MI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L
M:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;
M&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&
MG_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQ
MI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L
M:?\`\_2?K2_VOIY./M2?K5VBC`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]
M*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#TH
MP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`
M]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#T
BHP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]**__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
